Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Marker Therapeutics Inc (MRKR)

Marker Therapeutics Inc (MRKR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Marker Therapeutics (NASDAQ: MRKR) Announces Leadership Transition and Strategic Partnership with CellReady to Strengthen Financial Position Through 2025 Spotlight Growth - Mon May 1, 2023

Houston-based Marker Therapeutics, Inc. (Nasdaq: MRKR) operates as a clinical-stage company focused on developing advanced T cell-based immunotherapies for hematological

MRKR : 4.02 (-2.31%)
Author
Why Legend Biotech Stock Is Having Its Best Month Yet MarketBeat - Tue Apr 25, 2023

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

LEGN : 43.86 (-2.84%)
JNJ : 144.73 (-1.42%)
BMY : 44.05 (-1.32%)
NVS : 97.17 (+0.08%)
BIIB : 215.29 (-0.10%)
ALNY : 144.26 (-2.10%)
MRKR : 4.02 (-2.31%)
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates Zacks - Thu Nov 10, 2022

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

MRKR : 4.02 (-2.31%)
ENTA : 13.86 (+4.60%)
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma Globe Newswire - Thu Aug 4, 2022

Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023...

MRKR : 4.02 (-2.31%)
Marker Therapeutics Reports Q1 2022 Operating and Financial Results Globe Newswire - Fri May 13, 2022

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year...

MRKR : 4.02 (-2.31%)
Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting Globe Newswire - Wed May 4, 2022

HOUSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the...

MRKR : 4.02 (-2.31%)
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results Globe Newswire - Thu Mar 17, 2022

Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease...

MRKR : 4.02 (-2.31%)
Marker Therapeutics to Present at Two Upcoming March Investor Conferences Globe Newswire - Mon Mar 7, 2022

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the...

MRKR : 4.02 (-2.31%)
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion Globe Newswire - Wed Feb 16, 2022

Results from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in...

MRKR : 4.02 (-2.31%)
Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022 Globe Newswire - Tue Feb 8, 2022

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the...

MRKR : 4.02 (-2.31%)

Barchart Exclusives

2 Underperforming Dow Stocks That Morgan Stanley Recommends Buying Now Barchart - 31 minutes ago
Here are two Dow stocks that Morgan Stanley recommends buying now, despite lagging behind their parent index. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot